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http://dx.doi.org/10.1016/j.jmii.2012Background/Purpose: The aim of this study was to classify intensive care unit (ICU) bacterial
strains as either ICU-acquired or ICU-on-admission and to compare their epidemiological and
antibiogram characteristics.
Methods: The study was performed in a 1300-bed university-affiliated hospital from January 1,
2006 to December 31, 2010. Based on the time of ICU admission, ICU isolates were classified as
ICU-acquired strains (appearing more than 48 hours after admission) or ICU-on-admission
strains (appearing 48 hours or less from admission). The microbiological data before ICU admis-
sion, the microbiological data, and susceptibility testing were compared between the ICU-
acquired and ICU-on-admission bacterial isolates.
Results: The most common ICU-acquired strains were Acinetobacter baumannii (19.5%), Pseu-
domonas aeruginosa (15.6%), Stenotrophomonas maltophilia (11.5%), Staphylococcus aureus
(10.7%), Enterococcus spp. (10.6%), and Klebsiella pneumoniae (9.7%). There were significant
differences between ICU-acquired and ICU-on-admission isolates in the susceptibility rates of
Gram-negative bacteria to antibiotics, especially the susceptibility of A. baumannii to imipe-
nem [23.8% (ICU-acquired) vs. 44.4% (ICU-on-admission), p < 0.001] and meropenem (24.1% vs.
37.8%, p < 0.001), and the susceptibility of P. aeruginosa to imipenem (39.3% vs. 76.1%,Er Road, Shanghai 200025, China.
.com.cn (H. Qu).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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88 R. Tan et al.p < 0.001) and meropenem (58.5% vs. 76.1%, p < 0.05). Furthermore, decreased susceptibility
rates of A. baumannii and P. aeruginosa to carbapenems were correlated with an extended ICU
stay (p < 0.05).
Conclusion: Because of decreasing susceptibility rates of pathogens (especially ICU-acquired
strains) and a significant correlation with the length of ICU stay, intensivists should consider
a patient’s time of ICU admission and previous microbiological data and should distinguish
ICU-acquired strains from non-ICU-acquired strains so as to initiate optimized empirical anti-
biotic therapy against ICU-acquired infections.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Nosocomial infection has become an important worldwide
public health problem and increases morbidity, mortality,
and cost during a patient’s hospital stay.1e4 The preva-
lence of infections acquired in intensive care units (ICUs)
is even higher than it is in general wards because of the
severity of diseases, prolonged ICU and hospital stays,5
immunosuppression of ICU patients, and greater number
of interventions with invasive devices such as central-line
catheters, invasive mechanical ventilations, Foley urine
catheters.6,7
An ICU-acquired infection is defined as an infection
occurring more than 48 hours after an ICU admission.8 In
a recent multicenter study involving 71 adult ICUs, 7.4% of
the 9493 patients had an ICU-acquired infection.9
ICU-acquired infections commonly include a central line-
associated bloodstream infection (CLBSI, 40%), catheter-
associated urinary tract infection (CAUTI, 31%),
ventilator-associated pneumonia (VAP, 20%), and surgical
site infection (SSI, 9%).10,11 These ICU-acquired infections
are the most common complications for patients during ICU
stays and contribute to significant morbidity and
mortality.12
Local epidemiological data and antibiograms are useful
for optimized empirical antibiotic therapy for severe ICU-
acquired infections. Antimicrobial susceptibility of path-
ogens can vary markedly between hospitals and different
units within the same hospital. It is therefore necessary to
monitor prevalence and antimicrobial susceptibility
patterns to modify antimicrobial hospital policy, espe-
cially in ICUs. However, since many ICU admissions are the
result of substantial infections,9,13,14 most epidemiolog-
ical studies on ICU-acquired bacterial strains include
strains obtained outside the ICU. They thus have a bias
with respect to actual antibiotic resistant patterns. Few
epidemiological data are available on the prevalence,
distribution, and antibiogram of ICU-acquired and ICU-on-
admission strains (excluding “ICU” strains that are actu-
ally non-ICU strains).
The aim of this study was to classify ICU strains as ICU-
acquired or ICU-on-admission, based on the length of time
from the ICU admission [greater than 48 hours (ICU-
acquired) or up to 48 hours from admission (ICU-on-admis-
sion)]. The microbiological data was classified before ICU
admission. The epidemiological and antibiogram charac-
teristics were compared.Methods
Hospital settings
The study was performed at Ruijin Hospital (Shanghai,
China), a 1300-bed university-affiliated hospital, from
January 1, 2006 to December 31, 2010. Ruijin Hospital has
three ICUs: a 12-bed surgical ICU (SICU) in which surgical
intensive care patients and postoperative patients are
cared for; a 10-bed respiratory ICU (RICU) in which general
intensive care patients, especially patients with respiratory
dysfunction, are cared for; and an 18-bed emergency ICU
(EICU) in which most patients had been admitted from the
emergency department.
Definitions
ICU isolates were classified as either ICU-acquired strains or
ICU-on-admission strains. An ICU-acquired strain was
defined as a bacterial species that was obtained more than
48 hours after the patient’s ICU admission,15 whereas an
ICU-on-admission isolate was defined as a bacterial species
that was obtained within 48 hours after the patient’s ICU
admission.
An extensively drug-resistant (XDR) pathogen was
defined as a pathogen isolate that was resistant to all
currently available systemic antibiotics such as cephalo-
sporins, aztreonam, carbapenems, aminoglycosides, fluo-
roquinolones, and sulbactam (except for polymyxin B).16
Patients
Patients younger than 18 years old, patients whose ICU stay
was either less than 72 hours or longer than 3 months, and
patients readmitted to any ICU within 3 months were
excluded from the comparison of the epidemiological and
antibiogram characteristics of ICU-acquired and ICU-on-
admission isolates.
Microbiological data and susceptibility testing
For patients admitted to ICU and then once weekly during
their ICU stays, urine specimens and specimens from
sputum or endotracheal tube aspirates were regularly
collected and cultured for bacteria and fungi. Sputum,
endotracheal aspirates, oral swabs, urine, blood,
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clinical indications of infections during patients’ ICU stays.
All bacteria isolated were included in the study.
Data for in vitro susceptibility testing were collected
from the microbiological laboratory during a 5-year period
(2006e2010). The identification of bacterial species was
performed according to the criteria of the American Society
for Microbiology (ASM) and in vitro susceptibility testing
was performed according to the breakpoint definitions of
the Clinical and Laboratory Standards Institute (CLSI,
Wayne, PA). Antibacterial susceptibility testing for the
most commonly used antibiotics for a given microorganism
was routinely performed for all potential pathogens iso-
lated from any sample site. This testing was not repeated
when a microorganism was isolated more than once in the
same patient within 4 days. All isolates for which antibac-
terial susceptibility testing had been performed were
recorded in a computer database. The database excluded
redundancies of strains (i.e., the same microorganism with
the same antibiotic susceptibility pattern detected in
a separate isolate from the same patient). Antibiograms
were retrospectively calculated for each year from 2006 to
2010 for the most frequent Gram-positive and Gram-
negative bacteria and for the most commonly prescribed
antibiotics in the institution. The following microorganisms
were selected because of their prevalence and because of
the relevance of their susceptibility pattern in the choice of
empirical antibacterial therapy: Pseudomonas aeruginosa
(amikacin, gentamicin, ciprofloxacin, piperacillin, piper-
acillin/tazobactam, ceftazidime, cefepime, imipenem,
meropenem, cefaperazone/sulbactam); Acinetobacter
baumannii (amikacin, gentamicin, trimethoprim-
sulfamethoxazole, ciprofloxacin, piperacillin, piperacillin/
tazobactam, ceftazidime, cefepime, imipenem, mer-
openem, cefaperazone/sulbactam); and Staphylococcus
aureus (oxacillin, vancomycin, linezolid, teicoplanin).
Antibiograms were extracted for the whole institution, for
the three ICUs (i.e., SICU, RICU, and EICU), and for the ICU-
acquired strains and for the ICU-on-admission strains.Table 1 Isolate numbers and prevalence of clinical isolates in
Bacteria
Hospital
(n Z 24,764)
ICU
(n Z
Gram-positive isolates
Staphylococcus aureus 2,826 (11.4%) 332 (
CNS 2761 (11.1%) 168 (
Enterococcus faecalis 1673 (6.8%) 73 (
Enterococcus faecium 945 (3.8%) 166 (
Gram-negative isolates
Escherichia coli 5414 (21.9%) 217 (
Klebsiella pneumoniae 2320 (9.4%) 246 (
Acinetobacter baumannii 2115 (8.5%) 481 (
Pseudomonas aeruginosa 2230 (9.0%) 397 (
Stenotrophomonas maltophilia 1058 (4.3%) 309 (
Enterobacter 689 (2.8%) 86 (
Proteus 449 (1.8%) 26 (
CNS Z coagulase-negative staphylococci; EICU Z emergency inten
intensive care unit; SICU Z surgical intensive care unit.Statistical analysis
Data are presented by number of isolates and their
percentages. Comparative analysis was performed by using
the chi-square test for categorical variables. Two-tailed
tests were performed with the significance set at p less
than 0.05. The software used for analysis was SPSS 17.0
(SPSS Inc., Chicago, IL, USA) with Bonferroni corrections for
multiple tests.
Results
Comparison of epidemiological and antibiogram
characteristics between ICU and hospital-wide
settings
Prevalence and distribution of the clinical isolates
For the whole hospital, 24,764 strains were isolated during
the study period; 9116 (36.8%) were Gram-positive strains,
and 15,648 (63.2%) were Gram-negative strains. The most
common isolates were Escherichia coli (21.9%), S. aureus
(11.4%), Klebsiella pneumoniae (9.4%), P. aeruginosa
(9.0%), and A. baumannii (8.5%). Among the 2711 ICU
strains, 28.8% were Gram-positive strains and 71.2% were
Gram-negative strains. The most commonly isolated strains
were A. baumannii (17.7%), P. aeruginosa (14.6%), S. aureus
(12.3%), Stenotrophomonas maltophilia (11.4%), and K.
pneumoniae (9.1%) (Table 1).
When isolates were stratified according to specimen
type, the epidemiology and distributions were significantly
different among the different specimen types and between
the hospital and ICU isolates of the same specimen type.
For the whole institution, A. baumannii, P. aeruginosa, K.
pneumoniae, and S. aureus were the most commonly iso-
lated pathogens in respiratory tract samples, whereas E.
coli, Enterococcus faecalis, and E. faecium were common
in urine and bile samples. E. coli, S. epidermidis, and K.
pneumoniae were the top three pathogens obtained fromthe hospital and intensive care unit settings
Isolate no. (%)
2711)
RICU
(n Z 705)
SICU
(n Z 1225)
EICU
(n Z 781)
12.3%) 82 (11.3%) 144 (11.8%) 106 (13.6%)
6.2%) 47 (6.7%) 78 (6.4%) 43 (5.5%)
2.7%) 17 (2.4%) 39 (3.2%) 17 (2.2%)
6.1%) 20 (2.8%) 109 (8.9%) 37 (4.7%)
8.0%) 27 (3.8%) 128 (10.4%) 61 (7.8%)
9.1%) 77 (10.9%) 94 (7.7%) 75 (9.6%)
17.7%) 138 (19.6%) 187 (15.3%) 156 (20.0%)
14.6%) 117 (16.6%) 166 (13.6%) 114 (14.6%)
11.4%) 101 (14.3%) 135 (11.0%) 73 (9.3%)
3.2%) 21 (3.0%) 47 (3.8%) 18 (2.3%)
1.3%) 7 (1.0%) 12 (1.0%) 7 (0.9%)
sive care unit; ICU Z intensive care unit; RICU Z respiratory
90 R. Tan et al.blood samples. For ICU settings, A. baumanii was predom-
inant in the respiratory tract, in catheters, and in blood
samples. Enterococcus faecium, E. coli, and P. aeruginosa
were common in urine samples from ICU patients. A
significant decreasing trend was observed in the prevalence
of S. aureus and A. baumannii in the RICU during the
analysis. S. aureus decreased from 15.5% to 3.8% and A.
baumannii decreased from 27.7% to 7.8% (Fig. 1).
Comparison of antibiograms for hospital-wide and ICU
settings
During the 5-year period for either the ICU or the hospital,
a trend of decreasing antibiotic susceptibility was present
in commonly separated strains (p < 0.001). There were also
significant differences between the ICU and the hospital
antibiograms (Table 2). For multidrug-resistant bacteria,
there was a significant difference between the hospital and
ICU settings in the prevalence of MRSA [67.3% (hospital) vs.
94.3% (ICU), p < 0.001]; XDR A. baumannii (26.5% vs. 39.1%,
p < 0.001); and XDR P. aeruginosa (7.6% vs. 11.8%, p < 0.01)
(Table 3).
Comparison of epidemiological and antibiogram
characteristics between ICU-acquired and ICU-on-
admission isolates
Prevalence and distribution of ICU isolates
There were 1094 patients enrolled and 2324 ICU strains
analyzed. Of the analyzed strains, 1746 (75.1%) were ICU-
acquired strains and 578 (24.9%) were ICU-on-admission
strains. The most common ICU-acquired strains were A.
baumannii (19.5%), P. aeruginosa (15.6%), S. maltophilia
(11.5%), S. aureus (10.7%), Entercoccus spp. (10.6%), and K.
pneumoniae (9.7%). However, the most common ICU-on-
admission strains were P. aeruginosa (19.6%), A. baumannii
(15.6%), K. pneumoniae (13.3%), Enterococcus spp. (12.4%),
S. aureus (10.6%), and E. coli (7.6%). The prevalence and
distribution of ICU-acquired and ICU-on-admission isolates
were similar among the various specimen types. For the ICU-
acquired strains, A. baumannii notably remained the leading
pathogen in all specimen types, except urine samples. For
blood samples, A. baumannii, S. aureus, and K. pneumoniae
were the dominant isolated pathogens.Figure 1. Prevalence of Staphylococcus aureus and Acine-
tobacter baumannii in the RICU.Comparison of antibiograms between ICU-acquired and
ICU-on-admission isolates
There were no significant differences in the antibiograms
of the Gram-positive strains (including S. aureus and
Enterococcus spp.) between ICU-on-admission and ICU-
acquired groups. For the following commonly isolated
Gram-negative strains, the antibiograms of were
compared between the two groups of isolates: A. bau-
mannii, P. aeruginosa, K. pneumoniae, and E. coli (Table
2). Differences in the susceptibility of A. baumannii to
amikacin, ceftazidime, cefepime, imipenem, meropenem
was observed between ICU-acquired and ICU-on-admission
strains. For P. aeruginosa, the susceptibility to amikacin,
imipenem, and meropenem differed significantly. Differ-
ences also existed in the susceptibility of K. pneumoniae
to cefoperazone/sulbactam and piperacillin/tazobactam
and in the susceptibility of E. coli to ceftazidime. When
the three ICUs were analyzed separately, the suscepti-
bility rates of A. baumannii and P. aeruginosa to carba-
penems tended to be lower in the ICU-acquired isolates
(data not shown).
Since the susceptibility rates significantly decreased in
the ICU-acquired strains (compared to the rates of ICU-on-
admission isolates)despecially for A. baumannii and P.
aeruginosa to carbapenemsdthe relationships between the
susceptibility rates of A. baumannii and P. aeruginosa to
carbapenems and the length of ICU stay were further
investigated by dividing the time of hospitalization into
three periods: 48 hours or less, from 48 hours to 7 days, and
more than 7 days. Fig. 2 illustrates the relationships
between the susceptibility rates and the ICU length of stay.
Decreased susceptibility rates of A. baumannii and P. aer-
uginosa to carbapenems were correlated with a prolonged
ICU stay (p < 0.05). An analysis of sputum specimens
showed that the susceptibility rate of P. aeruginosa to
meropenem decreased as a patient’s ICU length of stay
increased (Fig. 3).
Stratifications according to the site of sampling such as
sputum or endotracheal aspiration, oral swab, urine, blood,
catheters, bile, drainage showed no differences in suscep-
tibility between ICU-on-admission and ICU-acquired strains,
with the exception of the susceptibility of A. baumannii to
gentamicin [27.8% (ICU-on-admission) vs. 16.7% (ICU-
acquired), p < 0.05] and trimethoprim-sulfamethoxazole
(25.3% vs. 14.9%, p < 0.05); the susceptibility of P. aeru-
ginosa to amikacin (92.4% vs. 77.8%, p < 0.01) and imipe-
nem (69.6% vs. 40.6%, p < 0.01); the susceptibility of K.
pneumoniae to cefoperazone/sulbactam (92.3% vs. 57.8%,
p < 0.01); and the susceptibility of E. coli to ceftazidime
(84.6% vs. 54.7%, p < 0.05) and ciprofloxacin (30.8% vs.
7.5%, p < 0.05) for sputum or endotracheal aspiration
cultures.
The proportions of the multidrug-resistant strains were
compared between the ICU-on-admission and ICU-acquired
groups. No vancomycin-resistant Enterococci (VRE) were
observed during the study period. Between the ICU-
acquired and ICU-on-admission strains, no significant
differences were found in the proportions of MRSA, XDR A.
baumannii, and XDR P. aeruginosa or in the proportions of
extended spectrum beta-lactamase (ESBL)-producing K.
pneumoniae and E. coli (Table 3).
Table 2 Susceptibility rates of hospital-wide, ICU, ICU-acquired, and ICU-on-admission isolates
Susceptibility rate (%)
Hospital ICU ICU-acquired ICU-on-admission
Acinetobacter baumannii n Z 2115 n Z 481 n Z 340 n Z 90
Amikacin 48.6 25.4* 23.2 35.6**
Trimethoprim-sulfamethoxazole 37.6 15.9* 11.2 24.4**
Ciprofloxacin 37.4 14.2* 12.1 20.0
Piperacillin/tazobactam 39.5 16.0* 15.3 22.2
Cefaperazone/sulbactam 61.4 48.0* 41.5 50.0
Ceftazidime 41.8 16.4* 14.1 27.8**
Cefepime 41.4 17.6* 13.2 25.6**
Imipenem 55.8 31.8* 23.8 44.4**
Meropenem 55.1 31.2* 24.1 37.8**
Pseudomonas aeruginosa n Z 2230 n Z 397 n Z 272 n Z 113
Amikacin 76.1 77.0 80.9 89.4**
Ciprofloxacin 68.5 67.7 71 64.6
Piperacillin/tazobactam 74.3 64.1 68.4 69.9
Ceftazidime 73.7 60.7* 67.3 69.9
Cefepime 74.3 67.0 73.2 69.9
Imipenem 66.2 48.1* 39.3 76.1**
Meropenem 71.0 57.2* 58.5 76.1**
Klebsiella pneumoniae n Z 2320 n Z 246 n Z 169 n Z 77
Amikacin 88.3 73.3* 79.3 83.1
Ciprofloxacin 64.0 41.2* 52.7 49.4
Piperacillin/tazobactam 78.0 48.3* 56.8 71.4**
Ceftazidime 66.7 36.9* 66.3 66.2
Cefepime 66.8 36.3* 71.6 75.3
Imipenem 99.5 98.3 100.0 100.0
Meropenem 99.5 98.3 98.2 100.0
Escherichia coli n Z 5414 n Z 217 n Z 145 n Z 44
Amikacin 79.4 79.4 78.6 79.5
Ciprofloxacin 31.3 12.4* 15.2 20.5
Piperacillin/tazobactam 78.6 71.8 74.5 65.9
Ceftazidime 46.4 27.5* 68.3 50.0**
Cefepime 46.4 26.1* 60.7 50.0
Imipenem 89.2 99.3* 100.0 100.0
Meropenem 89.2 98.9* 100.0 95.5
ICU Z intensive care unit.
*p < 0.001, for comparisons between hospital-wide and ICU isolated strains.
**p < 0.05, for comparisons between ICU-acquired and ICU-on-admission strains.
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S. aureus remained the most commonly isolated Gram-
positive bacteria hospital-wide and in the three ICUs.
There was a trend of decreasing annual prevalence in theTable 3 Prevalence of multidrug-resistant bacteria in hospital-
Indi
Hospital
Methicillin-resistant Staphylococcus aureus 1902/2826 (67.3)
XDR Acinetobacter baumannii 561/2115 (26.5)
XDR Pseudomonas aeruginosa 170/2230 (7.6)
ESBL-producing Klebsiella pneumoniae 455/2320 (19.6)
ESBL-producing Escherichia coli 2350/5414 (43.4)
ICU Z intensive care unit; ESBL Z extended spectrum beta-lactamas
*p < 0.01, for comparisons between hospital-wide and ICU isolated sICU isolates. This decreasing prevalence of S. aureus was
significant in the RICU. The prevalence of S. aureus
remained stable from 2006 to 2008 in the RICU, ranging
from 11.3% to 15.47%. However, the prevalence decreased
significantly to 9.4% in 2009 and 3.8% in 2010. In 2008,wide, ICU, ICU-acquired, and ICU-on-admission isolates
cated resistant isolate no./Total isolate no. (%)
ICU ICU-acquired ICU-on-admission
313/332 (94.3)* 187/187 (100) 61/62 (98.4)
188/481 (39.1)* 154/340 (45.2) 32/90 (35.6)
47/397 (11.8)* 24/272 (8.8) 0/113 (0)
80/246 (32.5)* 48/169 (28.4) 19/77 (25.0)
100/217 (46.0)* 55/145 (37.9) 22/44 (50.0)
e; XDR Z extensively drug-resistant.
trains.
Figure 2. Relationship between length of ICU stay and susceptibility rates of Acinetobacter baumannii and Pseudomonas aer-
uginosa to carbapenems. *p < 0.05, for comparisons between 48 hours or less, from 48 hours up to 7 days, or more than 7 days.
**p < 0.01, for comparisons between 48 hours or less, from 48 hours up to 7 days, or more than 7 days.
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and contact isolation precautions and appropriate hand
hygiene were implemented to prevent cross-transmission.
Thus, these comprehensive interventions may have
decreased the prevalence of S. aureus.
Similar distributions and prevalence of Gram-positive
strains were observed; however, the distribution of Gram-
negative bacteria differed significantly between the
hospital-wide and ICU isolates. E. coli was the most
commonly isolated Gram-negative strain in the hospital,
whereas nonfermentative bacteria, especially A. bau-
mannii and P. aeruginosa, were the predominant ICU
strains17. When ICU isolates were further stratified as ICU-Figure 3. Relationship between susceptibility rates of Acineto
samples to carbapenems and the length of ICU stay. *p < 0.05, for c
7 days, or more than 7 days. **p < 0.01 for comparisons between e
7 days.on-admission or ICU-acquired strains, the epidemiology
and distribution of the isolates were similar. However, for
the ICU-acquired strains, A. baumannii remained the
leading pathogen in all specimen types, including sputum,
oral swabs, urine, blood, catheters, bile, and drainage.
Although further stratification of the ICU isolates into
ICU-acquired strains added little information to the prev-
alence and distribution of ICU settings, the results of the
present analysis showed significant differences between
ICU and hospital-wide antimicrobial susceptibility rates,
and between presumably ICU-acquired and ICU-on-
admission antibiograms. The comparison revealed similar
susceptibility rates among Gram-positive strains, whereasbacter baumannii and Pseudomonas aeruginosa from sputum
omparisons between either 48 hours or less, from 48 hours up to
ither 48 hours or less, from 48 hours up to 7 days, or more than
Bacterial colonization and infections in ICUs 93important differences existed among Gram-negative
strains,18 especially A. baumannii, P. aeruginosa, K. pneu-
moniae, and E. coli. These findings may guide the choice of
empirical antibiotic therapy when clinicians are confronted
with an ICU-acquired infection, although these data are
limited to certain clinical situations and specific for the
hospital and ICUs where the data were collected.19
Few epidemiological data are available on antibiograms
that compare ICU-acquired and ICU-on-admission acquired
strains (excluding “ICU” strains that actually are non-ICU
strains). The present study tried to distinguish presumably
ICU-acquired isolates from ICU-on-admission isolates, based
on the length of time from the admission the isolate
appeared (48 hours or less from admission or after 48 hours
from admission, respectively) and based on previous
microbiological data before the patient’s transfer to the
ICU. By doing this, the susceptibility rates were found to be
much lower to certain antibiotics in some Gram-negative
ICU-acquired strains (especially for A. baumannii and
P. aeruginosa to carbapenems), compared to the suscepti-
bility rate of ICU-on-admission strains. Decreased suscep-
tibility rate of A. baumannii and P. aeruginosa to
carbapenems furthermore was correlated with a prolonged
ICU stay (p < 0.05) when the ICU stay were further divided
as follows: within 48 hours, from 48 hours to 7 days, and
from 7 days or more.
The global spread of carbapenem-resistant P. aeruginosa
and A. baumannii is of great concern,11,20 given that car-
bapenems are often used to treat these infections in the ICU.
The significantly low susceptibility of ICU-acquired strains to
carbapenems may be related to the increasing use of car-
bapenems in ICUs, although the actual use of carbapenems
unavailable at this time in our study. According to Lamoth
et al.,21 the use of carbapenems is particularly high in the
ICU22 [e.g., 22 defined daily doses (DDDs) of imipenem and
meropenem vs., 4.5 DDDs of piperacillin/tazobactam per
100 bed-days]. The clinical use of carbapenems may
continue to increase with prolonged ICU stays.
Inadequate initial antimicrobial treatment in serious
infections increases mortality. Achieving adequate treat-
ment is increasingly difficult because of the increasing
prevalence of multidrug-resistant (MDR) pathogens. As
previously noted, the failure to recognize the presence of
MDR pathogens results in inadequate antibiotic therapy.
This oversight leads to increased mortality. This vicious
cycle can promote the increasing use of wide-spectrum
antibiotics and increasing resistance to these antibiotics.
Carbapenems continue to provide a valuable weapon as
bacterial resistance to the other classes of antibiotics
increases23; however, reports on carbapenem-resistant
bacteria such as A. baumannii and P. aeruginosa should
increasingly draw the attention of clinicians and microbi-
ologists since resistance to carbapenems may lead to the
failure of initial empirical antibiotic therapy in severe ICU-
acquired infections and thereby increase the morbidity and
mortality.
Because of the increasing difficulty in choosing initial
empirical antibiotics against possible MDR or XDR patho-
gens, clinical interventions for infection control may play
an important role in decreasing the prevalence of MDR
pathogens,24 and thereby break the vicious cycle. The
decreasing trend in the prevalence of A. baumannii in theRICU may be the result of a multifaceted intervention to
reduce XDR A. baumannii colonization and infection since
2008. The interventions included implementing contact
isolation precautions and appropriate hand hygiene, active
surveillance, cohorting patients who were colonized or
infected with XDR A. baumannii, and environmental
cleaning. Apisarnthanarak et al.16 also conducted a multi-
faceted intervention to control XDR A. baumannii infection,
and the efficacy of the intervention was supported by the
dramatically decreasing prevalence of XDR A. baumannii in
longterm follow-up. At least 38% of all nosocomial infec-
tions in the ICU may result from cross-transmission. The
real frequency may be even higher since the susceptibility
rates of these nonfermentative organisms in an ICU are
much lower in countries with limited resources than in
developed countries.25 Reducing the incidence of these
MDR pathogens with multifaceted interventions may be
crucial in improving the outcomes of ICU-acquired infec-
tions in developing countries.
This study has several limitations. First, it was a single-
center study. Since susceptibility rates vary among hospi-
tals and units, the results may not be representative and
reproducible in other institutions. Second, this study
included clinical data (not listed here) such as demographic
data, underlying diseases, mechanical ventilation days,
catheter days, and duration of ICU stay; however, indi-
vidual risk factors for infections with resistant microor-
ganisms were not analyzed. We further plan to investigate
and analyze the epidemiology of ICU-acquired infections,
risk factors, and outcomes. In addition, the 48-hour cutoff
point was chosen in accordance with the Centers for
Disease Control standard definitions of nosocomial infec-
tions,25 and the 7-day cutoff was chosen in accordance with
the study by Jean et al.20 However, incubation periods may
vary by the type of pathogen or by a patient’s underlying
conditions, which make distinguishing between cases of
ICU-acquired and ICU-on-admission colonization and infec-
tions difficult.
In conclusion, variability exists in the prevalence and
distribution of clinical isolated strains and in the suscepti-
bility rates of clinical isolates between hospital-wide and ICU
settings. Because of the decreasing susceptibility rates of
pathogens to antibiotic treatment (especially ICU-acquired
strains) and because of a significant correlation between the
susceptibility rates of A. baumannii and P. aeruginosa to
carbapenems with ICU length of stay, intensivists should
consider the amount of time from a patient’s ICU admission
and the patient’s previous microbiological data, and the
patient’s length of ICU stay, and distinguish between ICU-
acquired strains and “ICU” strains that are actually non-ICU
strains when initiating appropriate empirical antibiotic
therapy against ICU-acquired infections.
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